FCER2 and B-cell chronic lymphocytic leukemia: This study aimed to investigate the immunophenotyping data of patients with mature B‐cell malignancies, and whether a new combined score including CD43 and CD180 could improve the diagnostic value of CLL versus non‐CLL, particularly in CLL with CD5 or CD23 negativity.